Mia's Feed
Medical News & Research

Understanding the Delays in Dementia Diagnosis: Why It Takes Years to Identify the Disease

Understanding the Delays in Dementia Diagnosis: Why It Takes Years to Identify the Disease

Share this article

A new study reveals that dementia diagnosis often takes over 3.5 years after symptoms start, underscoring the urgent need for improved early detection and diagnostic pathways.

2 min read

Why Does Dementia Take Years to Diagnose?

Dementia is a complex condition that can be challenging to diagnose promptly. A new study reveals that, on average, individuals with dementia are diagnosed approximately 3.5 years after symptoms first appear. For early onset dementia, this delay extends to about 4.1 years.

Dementia affects over 57 million people worldwide, impairing memory, thinking, and communication. Diagnosing it is difficult because there is no single test, and its symptoms often resemble those of other illnesses. Early symptoms can be subtle, making detection even more challenging.

Early diagnosis is crucial, as it helps patients and families plan for the future and enables healthcare systems to provide timely, proactive care. Delays are influenced by factors such as patient and family hesitation, healthcare provider awareness, and the misattribution of early symptoms to normal aging.

Research led by Dr. Vasiliki Orgeta analyzed data from over 30,000 participants across 13 studies. Findings highlight the need for improved public awareness, better training for clinicians, and enhanced diagnostic pathways, especially for younger individuals and those with less common types of dementia like frontotemporal dementia.

Addressing these delays involves community education, healthcare provider training, policy reforms, and technological advancements like telehealth cognitive screening. The goal is earlier recognition and better management of dementia, ultimately improving outcomes for those affected.

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Advances in Gastric and GE Junction Cancer Treatment: Durvalumab Combined with FLOT Shows Promising Results at ASCO

A groundbreaking phase 3 trial shows that combining durvalumab with FLOT chemotherapy significantly improves outcomes for patients with resectable gastric and GE junction cancer, offering new hope in cancer treatment.

Innovative PET Technique Enables Monitoring of Engineered T Cells in Immunotherapy

A groundbreaking PET imaging method developed at TUM enables real-time tracking of engineered T cells during immunotherapy, promising safer and more effective treatments. Source: https://medicalxpress.com/news/2025-06-pet-based-technique-cells-immunotherapy.html

The Risks of Chemotherapy Enzyme Deficiency and the Importance of Genetic Testing

A tragic case underscores the vital importance of genetic testing before chemotherapy to prevent fatal toxicity caused by enzyme deficiencies. Learn why personalized medicine is crucial in cancer treatment.